{
  "run_id": "RUN_20260204_234342_996d5a3920e1",
  "timestamp": "2026-02-05T04:19:13.608608",
  "document": "Carcinoid-Syndrome.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/NLP4RARE/train/Carcinoid-Syndrome.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 1,
  "total_validated": 1,
  "total_rejected": 0,
  "total_investigational": 0,
  "drugs": [
    {
      "matched_text": "octreoscan",
      "preferred_name": "indium in-111 pentetreotide kit",
      "brand_name": "OCTREOSCAN",
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": "INJECTABLE",
      "route": "INJECTION",
      "marketing_status": "Prescription",
      "codes": {
        "rxcui": null,
        "mesh": null,
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "FDA_NDA",
          "code": "NDA020314",
          "display": null
        }
      ],
      "context": "e cases. However, there are also blood tests available, the most useful being chromogranin-A, often in combination with an imaging technique known as octreoscan, that may confirm the diagnosis of carcinoid syndrome even when urinary 5-HIAA is normal. This technique may also be helpful in indicating the presen",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_fda_approved_drugs.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    }
  ]
}